Literature DB >> 11920757

Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats.

Shigeki Tamura1, Atsuo Ohike, Rinta Ibuki, Gordon L Amidon, Shinji Yamashita.   

Abstract

The objective of this study is to investigate the role of P-glycoprotein (P-gp), a membrane efflux pump associated with multidrug resistance (MDR) and a known substrate for tacrolimus, in determining the regional intestinal permeability of tacrolimus in rats. Thus, isolated segments of rat jejunum, ileum, or colon were perfused with tacrolimus solutions containing polyethoxylated hydrogenated castor oil 60 surfactant, and with or without verapamil, a P-gp substrate used to reverse the MDR phenotype. The results indicated that the intrinsic permeability of tacrolimus in the jejunum, calculated on the basis of the concentration of non-micellized free tacrolimus, was quite high ( approximately 1.4 x 10(-4) cm/s). The apparent permeability (P(app)) in the jejunum was unaffected by the presence of verapamil; however, the P(app) in the ileum and the colon increased significantly in the presence of verapamil and were similar to the values observed in the jejunum. The results suggest that systemic absorption of tacrolimus from the gastrointestinal tract could be significantly affected by P-gp efflux mechanisms. It is also possible that differences in P-gp function at various intestinal sites in a subject or at a given intestinal site in various subjects could lead to large intra- and interindividual variability in bioavailability of tacrolimus following oral administration. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association .

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2002        PMID: 11920757     DOI: 10.1002/jps.10041

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  17 in total

Review 1.  Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.

Authors:  Adam S Darwich; Kathryn Henderson; Angela Burgin; Nicola Ward; Janet Whittam; Basil J Ammori; Darren M Ashcroft; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 2.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.

Authors:  Marija Tubic; Daniel Wagner; Hilde Spahn-Langguth; Michael B Bolger; Peter Langguth
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

4.  Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test.

Authors:  Yan-ping Wang; Yong Gan; Xin-xin Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-09-19       Impact factor: 6.150

5.  Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus.

Authors:  Vivek Borhade; Hema Nair; Darshana Hegde
Journal:  AAPS PharmSciTech       Date:  2008-01-04       Impact factor: 3.246

6.  Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells.

Authors:  Yu-Yuan Chiu; Kazutaka Higaki; Brien L Neudeck; Jeffrey L Barnett; Lynda S Welage; Gordon L Amidon
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

7.  Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing.

Authors:  Kirk A Overhoff; Jason T McConville; Wei Yang; Keith P Johnston; Jay I Peters; Robert O Williams
Journal:  Pharm Res       Date:  2007-10-30       Impact factor: 4.200

8.  The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.

Authors:  Arik Dahan; Hairat Sabit; Gordon L Amidon
Journal:  AAPS J       Date:  2009-03-25       Impact factor: 4.009

9.  P-glycoprotein increases from proximal to distal regions of human small intestine.

Authors:  Stéphane Mouly; Mary F Paine
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

10.  Formulation strategies for drug delivery of tacrolimus: An overview.

Authors:  Pranav Patel; Hitesh Patel; Shital Panchal; Tejal Mehta
Journal:  Int J Pharm Investig       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.